2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147633
    KRAS G12C inhibitor 52
    		Inhibitor
    KRAS G12C inhibitor 52 (Compound 7) is a KRAS G12C inhibitor.
    KRAS G12C inhibitor 52
  • HY-146432
    Antitumor agent-60
    		Inhibitor
    Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model.
    Antitumor agent-60
  • HY-163880
    EGFR-IN-119
    		Inhibitor
    EGFR-IN-119 (Compound 5l) is an inhibitor for EGFR with an IC50 of 84.3 nM. EGFR-IN-119 inhibits the cytotoxicity in lung cancer cell A549 with an IC50 of 1.34 μM. EGFR-IN-119 downregulates the expressions of EGFR, KRAS, and MAP2K genes, exhibits antioxidant activity through reduction of reactive oxygen species (ROS), and hyperpolarizes the mitochondrial membrane potential.
    EGFR-IN-119
  • HY-176523
    KRAS G12D-IN-29
    		Inhibitor
    KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective KRASG12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRASG12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRASG12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer).
    KRAS G12D-IN-29
  • HY-146533
    KRAS inhibitor-12
    		Inhibitor
    KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC50 of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC50s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-12
  • HY-143606
    KRAS G12D inhibitor 12
    		Inhibitor
    KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134).
    KRAS G12D inhibitor 12
  • HY-176288
    eIF4E/eIF4G PPI-IN-1
    		Inhibitor
    eIF4E/eIF4G PPI-IN-1 is an eIF4E/eIF4G interaction inhibitor with a KD of 20.2 μM for eIF4E protein. eIF4E/eIF4G PPI-IN-1 plays an antitumor role in multiple modes of action including regulating the activity of eIF4E by inhibiting the Ras/MAPK/eIF4E signaling pathway, apoptosis and cell migration. eIF4E/eIF4G PPI-IN-1 suppresses the growth of HepG2 xenografts in nude mice and was relatively nontoxic to mice.
    eIF4E/eIF4G PPI-IN-1
  • HY-144211
    SOS1-IN-7
    		Inhibitor
    SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.
    SOS1-IN-7
  • HY-177106
    ADT-1004
    		Inhibitor
    ADT-1004 is an inhibitor of RAS. ADT-1004 can be studied in research for Ras-mediated diseases.
    ADT-1004
  • HY-142948
    KRAS G12C inhibitor 46
    		Inhibitor
    KRAS G12C inhibitor 46 (compound WX003) is a potent KRAS G12C inhibitor.
    KRAS G12C inhibitor 46
  • HY-162441
    pan-KRAS-IN-8
    		Inhibitor
    pan-KRAS-IN-8 (Compound 38) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.07 and 0.18 nM, respectively.
    pan-KRAS-IN-8
  • HY-174243
    KRASG12D-IN-5
    		Inhibitor
    KRASG12D-IN-5 (Compound 241) is an orally active KRAS(G12D) inhibitor with an IC50 of 11 nM. KRASG12D-IN-5 has potent anticancer activity with no significant cytotoxicity against BxPC-3 (WT), KRAS mutation AsPC-1 (G12D) and MIAPaCa-2 cells (G12C) with CC50s of 10.37, 0.76 and 0.3 μM, respectively. KRASG12D-IN-5 can be used for cancer research, such as lung, pancreatic and colorectal cancer.
    KRASG12D-IN-5
  • HY-161177
    PROTAC KRAS G12D degrader 2
    		Inhibitor
    PROTAC KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPro). Protac KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPRO). The PROTAC molecule is designed by partially coupling a GC-376-based dipeptidyl 3CLPro ligand with pomadomide via a piperazine-piperidine linker.
    PROTAC KRAS G12D degrader 2
  • HY-158703
    KRAS G12D inhibitor 24
    		Inhibitor
    KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC50 of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity.
    KRAS G12D inhibitor 24
  • HY-174379
    KRAS IN-44
    		Inhibitor
    KRAS IN-44 (Compound S2C2M2) is a PDE6D degrader. KRAS IN-44 inhibits PDE6D-dependent KRAS trafficking and KRAS downstream signaling pathways. KRAS IN-44 down-regulates EGF-induced the phosphorylation of PI3K, AKT, and mTOR. KRAS IN-44 increases Apoptosis. KRAS IN-44 has antitumor activity against hepatoblastoma.
    KRAS IN-44
  • HY-153461
    KRAS G12C inhibitor 58
    		Inhibitor
    KRAS G12C inhibitor 58 is a KRAS G12C inhibitor, used in cancer research.
    KRAS G12C inhibitor 58
  • HY-161173
    PROTAC SOS1 degrader-5
    		Inhibitor
    PROTAC SOS1 degrader-5 (compound 4) is a potent PROTAC SOS1 degrader, with the DC50 of 13 nM. PROTAC SOS1 degrader-5 strongly inhibits NCI-H358 cells proliferation with an IC50 of 5 nM.
    PROTAC SOS1 degrader-5
  • HY-162446
    pan-KRAS-IN-13
    		Inhibitor
    pan-KRAS-IN-13 (compound 2) is a potent inhibitor of KRAS, with IC50s of 2.75 nM and 2.89 nM for G12D and G12V, respectively
    pan-KRAS-IN-13
  • HY-173405
    VVD-699
    		Inhibitor
    VVD-699 is a covalent RAS-PI3K inhibitor. VVD-699 covalently binds to cysteine 242 in the RAS binding domain of PI3K p110α, thereby blocking the ability of RAS to activate PI3K activity. VVD-699 is able to inhibit the growth of RAS-mutated and HER2-overexpressing tumors. VVD-699 can be used to study cancers associated with RAS mutations (e.g., H358 lung cancer cells, A549 cells, FaDu cells).
    VVD-699
  • HY-164350
    KRAS inhibitor-27
    		Inhibitor
    KRAS inhibitor-27 (Compound 15h) is the inhibitor for KRAS. KRAS inhibitor-27 inhibits KRAS G12D/G12V mutated cells AsPC-1, SW620 and KRAS wildtype cell HT-29 with IC50 of 378, 0.6 and 3230 nM, respectively. KRAS inhibitor-27 inhibits ERK phosphorylation (IC50 in cell AsPC-1 and SW620 is 0.6 nM and 1 nM), reduces the expression of DUSP4, thereby inhibiting MAPK signaling pathway.
    KRAS inhibitor-27
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.